Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals IncfiledCriticalAmira Pharmaceuticals Inc
Priority to UY0001032679ApriorityCriticalpatent/UY32679A/en
Publication of UY32679ApublicationCriticalpatent/UY32679A/en
Se describen aquí compuestos que son antagonistas de receptores lisofofosfatídicos . También se describen composiciones farmacéuticas y medicamentos que incluyen los compuestos descritos aquí, así como también métodos para utilizar tales antagonistas, solos o en combinación con otros compuestos, para tratar afecciones o enfermedades mediadas por LPA o dependientes de LPA.Compounds that are antagonists of lysophophosphate receptors are described herein. Pharmaceutical compositions and medicaments including the compounds described herein are also described, as well as methods for using such antagonists, alone or in combination with other compounds, to treat conditions or diseases mediated by LPA or LPA-dependent.
UY0001032679A2010-05-312010-05-31
POLYCHYCLIC ANTAGONISTS OF LISOPHOSPHYTIDIC ACID RECEPTORS
UY32679A
(en)
Compounds derived from pyrrolotriazinone as inhibitors of pi3k; pharmaceutical composition that includes them; pharmaceutical combination; use to treat respiratory, autoimmune, neurological, cardiovascular, metabolic disorders, among others.
Compounds derived from piperidinyl substituted lactams, modulators of gpr119; Preparation process; pharmaceutical composition that includes them; treatment method; and use of the compound to treat diseases such as type 2 diabetes, metabolic syndrome, dyslipidemia, hypertension and schizophrenia, among others.